Cortigent Inc - CRGT Forward Price-to-Revenue Multiple
A stable staff of neuroengineers and brain-computer interface experts ensures the technological growth of Cortigent, Inc. (CRGT). The forward price-to-sales valuation trend confirms capital inflows, and the metric currently stands at . This is supported by the company's status as a reliable brand in implant microelectronics, as well as diversification through the creation of motor and vision recovery systems for patients following severe injuries.
cortigent.com - analytical breakdowns and key metrics (CRGT)
- market price and analyst price targets:
- issuer market value details:
- business book valuation details:
- debt obligations and liquidity statistics:
- net income and valuation multiples indicators:
CRGT - Final Profit|Projected Future Earnings Cortigent, Inc.|CRGT - Market Cap to Net Income Ratio|Projected Price to Earnings Cortigent|CRGT - Company Value to Earnings Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CRGT|CRGT - Operating profit before amortization|Net earnings per share (EPS TTM) Cortigent|CRGT - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months cortigent.com|CRGT - Earnings growth in current year|Net earnings per share growth forecast for next year Cortigent, Inc.
- company sales and revenue statistics:
Analysis of all company metrics:Cortigent Medical (CRGT)
The forward P/S ratio measures the market value of Cortigent, Inc. relative to expected sales volume, determining the business's margin of safety amid changing fiscal conditions and subsidies. By analyzing the forward price-to-sales valuation, an investor can track the confidence levels in the Cortigent, Inc. model, which is supported by a unique staff of neural interface developers and compliance experts who ensure technological superiority and the sustainability of future cash flows.
Analysis of competing companies
Price-to-Projected Revenue Ratio Biogen BIIB|NBIX: Market Cap to Projected Revenue|RGC: Forward Price-to-Revenue Multiple|Axsome Corp - Price to Expected Revenue Ratio|ACAD (ACADIA Pharmaceuticals) - Forward Price-to-Revenue Multiple|xenon-pharma.com - Forward Price to Sales|VKTX (Viking Therapeutics, Inc.) - Forward P/S Multiple|Supernus Pharmaceuticals, Inc. (SUPN) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Catalyst Pharmaceuticals Inc (CPRX)|Denali Corp - Market Cap to Projected Revenue|Forward P/S Multiple HRMY (Harmony Biosciences)|BHVN - Forward Price-to-Revenue Multiple|AMLX: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Trevi Therapeutics Inc TRVI|PRAX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Anavex Life Sciences Corp|Price-to-Projected Revenue Ratio CeriBell, Inc.|PRTA: Forward Price to Sales|Forward P/S Multiple ALEC|Annexon Biosciences (ANNX) - Projected Price to Revenue|Omeros - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio NGNE (Neurogene Therapeutics)|ACIU - Price-to-Projected Revenue Ratio|VYGR (voyagertherapeutics.com) - Market Cap to Projected Revenue|NMRA: Forward P/S Multiple|Market Cap to Future Revenue Ratio Scilex Holding (SCLX)|Forward Price-to-Revenue Multiple TVGN|Forward P/S Multiple Alpha Cognition Corp|Price-to-Projected Revenue Ratio Cognition Therapeutics (CGTX)|IKT (inhibikase.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio Cassava Sciences SAVA|Assertio Holdings (ASRT) - Market Cap to Future Revenue Ratio|Coya - Forward P/S Multiple|Vistagen Therapeutics (VTGN) - Forward Price-to-Revenue Multiple|ovidrx.com (OVID) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio acumenpharm.com (ABOS)|Price-to-Projected Revenue Ratio CervoMed|ATHE: Forward Price to Sales|Forward Price-to-Revenue Multiple CLNN (Clene Inc.)|Price to Expected Revenue Ratio PEPG|Forward P/S Multiple JUNS (Jupiter Neurosciences Inc)|Market Cap to Expected Sales Ratio relmada.com (RLMD)|Annovis Bio - Forward P/S Multiple|Projected Price to Revenue Grace Therapeutics, Inc. (GRCE)|AIFF: Forward P/S Multiple|Market Cap to Future Revenue Ratio Klotho Neurosciences (KLTO)|Price-to-Projected Revenue Ratio NeuroSense Therapeutics Ltd|Market Cap to Projected Revenue RVPH (revivapharma.com)|Forward Price-to-Revenue Multiple MTVA (MetaVia Inc)|Price to Expected Revenue Ratio NRXS|Helius Medical Technologies - Forward Price-to-Revenue Multiple|Forward Price to Sales PASG|Neuphoria - Forward P/S Multiple|Market Cap to Expected Sales Ratio minervaneurosciences.com NERV|Athira Pharma (ATHA) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue ADXN|ALZN (Alzamend Neuro Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Cyclerion (CYCN)|Forward Price-to-Revenue Multiple PTIX (Protagenic Therapeutics)|Market Cap to Expected Sales Ratio pasitheaclinics.com|Forward P/S Multiple ATXI (Avenue Therapeutics, Inc.)|BCLI - Forward Price-to-Revenue Multiple|CARA - Price-to-Projected Revenue Ratio|Forward Price to Sales CHRO (Chromocell)|ELYM: Forward P/S Multiple|Projected Price to Revenue Intra-Cellular Therapies, Inc. ITCI|Forward Price-to-Revenue Multiple LBPH|MRNS (Marinus Pharmaceuticals Inc) - Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio NKGen (NKGN)|NeuroBo Pharma - Market Cap to Projected Revenue|Forward P/S Multiple SAGE (Sage Therapeutics, Inc.)|synaptogen.com (SNPX) - Market Cap to Future Revenue Ratio|TRVN: Forward Price-to-Revenue Multiple|VIGL - Forward P/S Multiple|Anew Medical (WENA) - Price-to-Projected Revenue Ratio|Cerevel Corp - Forward Price to Sales
